在ALS中,托弗森和其他反感性寡核酸
Albert Ludolph1,2, Maximilian Wiesenfarth3
1Department of Neurology, Ulm University, Oberer Eselsberg 45, Ulm 89081, Germany.
Therapeutic advances in neurological disorders
|January 23, 2025
概括
反感性寡核酸 (ASO) 疗法在治疗神经退行性疾病,如SOD1 - 氨基转移性侧面硬化症 (ALS) 方面表现有前途. 托弗森是一种ASO,在SOD1-ALS患者中对生物标志物和功能结局产生有益影响.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 遗传学 是一个
- 药理学 药理学是指药理学的学科.
背景情况:
- 反感性寡核酸 (ASO) 疗法为神经退行性疾病提供了新的希望.
- 努辛森已经在脊髓肌肉缩,一种衰退性疾病中取得了成功.
- 超氧化物失致酶1 (SOD1) 缩性侧面硬化症 (ALS) 是主导性神经退行性疾病的关键标.
研究的目的:
- 评估ASO托弗森在治疗SOD1-ALS中的疗效.
- 了解托弗森对生物标志物和功能结果的机械效应.
- 探索有关SOD1-ALS.的ASO治疗的潜在改善和未解决的问题.
主要方法:
- 临床试验涉及对SOD1-ALS患者进行托弗森治疗.
- 机械和退行性生物标志物的监测.
- 功能性结果的评估,包括体重稳定和ALSFRS-R分数.
主要成果:
- 托弗森在SOD1-ALS患者中表现出令人信服的有益作用.
- 在动物中进行的临床前研究准确预测了人类的治疗效果.
- 临床疗效与生物标志物的顺序变化和功能改善相关.
结论:
- 托弗森对SOD1-ALS具有显著的治疗潜力,验证了临床前预测.
- 需要进一步的研究来阐明精确的作用机制和长期影响.
- 调查潜在的副作用,自身免疫反应和预防策略对于优化ASO治疗至关重要.
相关概念视频
Alzheimer's Disease: Treatment
160
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
160
siRNA - Small Interfering RNAs
16.5K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.5K
Parkinson's Disease: Treatment
198
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
198
Drugs Affecting Neurotransmitter Synthesis
1.2K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.2K
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
653
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
653


